Burden of early, advanced and metastatic breast cancer in The Netherlands


Abstract

Background: The aim of this study was to estimate the total economic and health related burden of breast cancer in the Netherlands.

Methods: Data on incidence, prevalence, mortality and survival were extracted from the Dutch National Cancer Registry and were used to calculate the economic and health related burden of breast cancer for overall, DCIS (stage 0), early- (stage I), locally advanced- (stage II-III) and metastatic- (stage IV) breast cancer by age groups and by year (if applicable).

Results: The overall incidence of breast cancer increased from 103.4 up to 153.2 per 100,000 women between 1990 and 2014. The increase was driven by DCIS and early breast cancer as the incidence of locally advanced and metastatic breast cancer remained stable. Between 1990 and 2014, ten-year overall survival rates increased from 87% to 93% for early breast cancer, 41% to 62% for locally advanced- and from 6% to 9% for metastatic disease. Annually, breast cancer in the Netherlands is responsible for approximately 3100 deaths, 26,000 life years lost, 65,000 Disability Adjusted Life Years (DALYs) and an economic burden of €1.27 billion.

Conclusions: This study provides a comprehensive assessment of the burden of breast cancer and subsequent trends over time in the Netherlands.

Keywords: Breast cancer burden costs incidence prevalence mortality early advanced metastatic

Background

Breast cancer is the most common cancer and leading cause of cancer-related mortality amongst women worldwide [1, 2]. Together with lung, colorectal and prostate cancer, breast cancer contributes to half of the overall burden of cancer mortality in Europe [3]. In Europe approximately 500,000 women are diagnosed with breast cancer annually and in 2012, breast cancer cases were responsible for a third of all cancer related deaths (131,259) [4]. The incidence and prevalence of breast cancer increased over the past decades due to the progressive nature of the disease and the aging population in Western countries [1]. In 2010, the lifetime risk of developing breast cancer was 1 in 6.6 women in the Netherlands while the lifetime risk of breast cancer death was 1 in 27 [5]. Furthermore, it has been shown that the Netherlands has a breast cancer related Disability Adjusted Life-Year (DALYs) burden of approximately of 1100 DALYs per 100,000 women [6].

Several previous studies aimed to assess the burden of breast cancer. However, to our knowledge, there is currently no study available assessing both the economic and health Burden of Disease (BoD) stratified by stage using data from a national cancer registry over a 24 year period [7, 8]. Stratification by stage of
diagnosis is necessary, since the burden of disease differs between disease stages [7]. Mapping the stage stratified breast cancer burden over time also enables adequate evaluation of policy implementation and decision making, for instance regarding the mammographic screening program [9]. In addition, this will provide new insights into the difference in morbidity and mortality between early, locally advanced and metastatic breast cancer.

The aim of this study is to describe the total health and economic related burden of breast cancer in the Netherlands. The total burden of breast cancer is expressed in economic costs per year, incidence, prevalence, survival, mortality, life-years lost and DALYs. The results of this study can be used to facilitate healthcare decision making, resource allocation and investment studies.

Methods
Data source
Breast cancer incidence, prevalence, survival and mortality data between 1990 and 2014 were obtained from the Netherlands Comprehensive Cancer Organization (IKNL) and the National Cancer Registry (NCR) [10]. As survival data within this database is generated in cohorts, most recent 10-year survival was available until 2009. Additionally, data was available for up to 4-year survival in the latest cohort (2010–2013). Tumors in this registry are coded according to the International Classification of Diseases for Oncology (ICD-O). Regarding multiple primary cancers, the registry follows the guidelines developed by the International Agency for Research on Cancer (IARC) and the International Association of Cancer Registries (IACR). In this study we differentiate between early, locally advanced and metastatic breast cancer based on the Tumour Node Metastasis (TNM) classification and IACR guidelines [11, 12]. Stage 0 (DCIS) and Stage I were defined as early breast cancer, stages II to III as locally advanced breast cancer, and stage IV was labeled as metastatic breast cancer. In the performed analyses (see below), the results are reported per separate stage where possible. This distinction was made based on the differences in treatment guidelines with recommendations ranging from breast-conserving surgery to mastectomy, radiation therapy, chemotherapy, hormone therapy, or a combination of different treatments in stage IV [13, 14].

Incidence, prevalence, and mortality
Incidence, prevalence and mortality data were both obtained in crude rates (absolute number of cases in the Netherlands), and in European Age Standardized Rates (ESR) (cases per 100,000 women, corrected by age for the European geographic composition). DCIS is not included in the survival analysis. Up to 10-year overall survival data (over the period 1989–2009) were available. For the most recent data a sub-analysis consisting of 4-year survival data from the period 2010–2013 was included. When applicable, results are presented in five-year age groups starting at the age of 15 (e.g. 15–19, 20–24, etc.) up to 95, after which the age band is open including all subject aged 95 years and older.

DALY burden
The Disability Adjusted Life-Year (DALY) is a measure to express the BoD. DALYs represent the number of healthy life lost due to a disease or risk factor. One DALY can be regarded as 1 lost year of “healthy life”. It is calculated by adding the years of life lost due to premature mortality (YLL) to the years lived with disability (YLD, morbidity). YLL regards the sum of years that a person would have lived if the individual would not have the current disease under study and was based on the average life expectancy of women in the Netherlands [15]. YLD expresses the consequences of living with a less than perfect health condition, and is estimated based on the length of time with that condition and the corresponding disability weight. The parameters used to estimate DALYs are mortality, incidence, average duration to death or cure from breast cancer, the disability weight of living with breast cancer and the age at diagnosis. Based on the EUROCARE-4 study, we estimated that the median duration of cancer until patients were either cured or deceased was 4.3 years [16]. This number was subsequently used to calculate the YLL. The Disability weight was assessed at 0.38, that was derived from Disability Weights for Diseases in the Netherlands study, being the average disability weight of all disease stages, weighted by its duration and cure rate [17]. A discount rate of 1.5% was applied to both YLL and YLD, which is the standard discount rate in the Netherlands for discounting health outcomes and utilities. Additionally, the DALY burden was calculated without inclusion of DCIS. The metrics on how DALYs were calculated can be found in Additional file 1.

Economic burden
The total healthcare expenditure due to breast cancer in the Netherlands was obtained from the
cost of illness database by the national institute for public health (RIVM). Data were available for 2003, 2005, 2007 and 2011. This database is a product of the Dutch government and was used for policy and healthcare decision making. The costs include public healthcare and prevention, costs for 1st line care, hospital & medical professional care, elderly care, drugs, management and costs of other healthcare providers, as derived from the national cost of illness database [18]. The costs of breast cancer in 2014 were estimated by extrapolating those from 2011 using Dutch Customer Price Index (CPI) inflation rates [19]. Productivity losses due breast cancer-related morbidity and mortality in the Netherlands were estimated using the human capital approach (more details on the exact methods and equations used to calculate these indirect non-medical costs can be found in Additional file 1). All prices in this study are expressed in 2014 Euros.

Sensitivity analysis
Univariate sensitivity analysis was used to investigate the sensitivity of the base-case estimates to variation in several parameters. The gross domestic product growth rate, used for the prediction of future growth rate, was varied to 0%, 1.5% and 3.5%, to account for uncertainty over future growth in the Dutch economy. The discount rate for costs was varied between 2% and 6%. Female Gross Labor participation was adjusted to match the amount of men, to account for future emancipation. Work-Absence rates were varied by ±10% to investigate the sensitivity of this estimate on productivity losses due to morbidity. In addition, the effect of extending the retirement age from 65 to 66 and 67 was explored, to account for potential changes in the official retirement age in the Netherlands. For productivity losses due to mortality, we varied the results by using the friction cost method, which only takes the friction period of 85 calendar days in consideration for potential loss of productivity [20].

Results
Absolute cases, incidence, and prevalence
In total 320,179 women were diagnosed with breast cancer in the Netherlands between 1990 and 2014. The absolute overall number of cases per year increased from 8233 in 1990 up to 16,688 in 2014 (see Table 1 and Appendix Figure 1). This increase was mainly due to the 231% increase in cases of early breast cancer (including DCIS) from 2682 to 8869. During the same period, the number of locally advanced breast cancer cases also increased by 40% and metastatic disease increased by 43%. When excluding DCIS from the analysis the absolute overall number of incident breast cancer cases increased from 7913 in 1990 to 14,541 in 2014.

The overall incidence increased from 103/100,000 in 1990 to over 153/100,000 women in 2014 (Table 1 and Fig. 1). The increase in the incidence was mainly attributable to an increase of early breast cancer diagnosis (from 34.6/100,000 to 82.7/100,000 women). In particular the incidence of DCIS increased by 386% (from 4.2/100,000 to 20.4/100,000). Overall the incidence of locally advanced breast cancer was stable (3% increase). However, within more advanced disease stages, there were large differences with a decline of 5% for both stage II and stage IIIb/c and an increase of 115% in stage IIIa. Finally, the incidence of metastatic breast cancer (stage IV) remained stable during the study period.

The 5-year prevalence of breast cancer increased by 77% (from 41,476 in 1995 towards 73,261 in 2014). The 10-year prevalence (available from 2000

<table>
<thead>
<tr>
<th>Period</th>
<th>Early Breast Cancer</th>
<th>Advanced Breast Cancer</th>
<th>Metastatic</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DCIS</td>
<td>Total</td>
<td>II</td>
<td>Illa</td>
</tr>
<tr>
<td>1990</td>
<td>4.2</td>
<td>30.4</td>
<td>34.6</td>
<td>51.7</td>
</tr>
<tr>
<td>1995</td>
<td>10.0</td>
<td>43.4</td>
<td>53.4</td>
<td>51.9</td>
</tr>
<tr>
<td>2000</td>
<td>12.2</td>
<td>48.1</td>
<td>60.3</td>
<td>58.5</td>
</tr>
<tr>
<td>2005</td>
<td>12.3</td>
<td>50.4</td>
<td>63.7</td>
<td>49.7</td>
</tr>
<tr>
<td>2010</td>
<td>19.3</td>
<td>60.3</td>
<td>79.6</td>
<td>45.8</td>
</tr>
<tr>
<td>2014</td>
<td>20.4</td>
<td>62.3</td>
<td>82.7</td>
<td>49.1</td>
</tr>
</tbody>
</table>

Percentage increase
(+ 386% (+ 105%) (+ 139% (-5% (+ 31% (+ 115% (-5% (+ 3% (+ 1% (+ 102%)
(+ 565%) (+ 185%) (+ 231%) (+ 188%) (+ 42.7%) (+ 103%)
**Fig. 1** European Standardized breast cancer incidence rates per 100,000 women stratified by stage of diagnosis between 1990 and 2014 for the Netherlands. Vertical lines represent changes in TNM.

**Fig. 2** Proportionate stage at diagnosis per age group for the year 2014.
onwards) increased by 58% (from 78,892 to 124,996).

**Proportional distribution by stage over time and by age**

The proportion of women diagnosed with early breast cancer (including DCIS) increased from 33% in 1990 to 54% in 2014. During the same period, we observed a reduction in the proportion of locally advanced breast cancer (from 60% to 42%) and metastatic disease (from 6% to 4%). Additional analysis showed that the proportion early breast cancer increased from 31% in 1990 to 47% in 2014 while locally advanced and metastatic decreased from 63% and 7% to 48% and 5% respectively when DCIS was excluded.

Figure 2 shows the proportional distribution by stage at diagnosis per age group for 2014. It clearly shows that the proportion of early stages of breast cancer is highest in the group of women aged between 50 and 74, which corresponds to the breast cancer screening-bracket in the Netherlands (50 to 75 years). Also the incidence (in absolute annual numbers) is higher in the age groups within the screening brackets (Fig. 3). This is also true for locally advanced and metastatic incidence. The exception is that the number of cases of locally advanced disease is higher in the 45 to 49 year old group compared to the age groups within the 55 to 75 years range.
Survival rates

Figure 4 shows the overall survival for early, locally advanced and metastatic breast cancer between 2003 and 2009 (6th TNM edition). It clearly shows the large impact of stage at diagnosis. For example, 5 years after diagnosis the overall survival was 98% for early breast cancer, 85% for locally advanced and 22% for metastatic disease. After 10 years, these numbers are 94%, 75% and 9%. Survival data specified per cancer stage from Ia to stage IV is available in the Additional file 1.

An increase in survival was observed for all stages of breast cancer compared to historical survival data (see Additional file 1: Tables S1-S5). Accordingly, the most recent data in the 7th TNM edition show a slight increase in survival. Although our data analysis regarded a limited period of four-years (2010–2014), we observe an increase in overall survival of 1% for early breast cancer, 1% locally advanced and 4% metastatic breast cancer in comparison with the previous survival data from the 6th TNM edition.
Deaths, life years and DALYs lost
In total 84,282 women died of breast cancer in the Netherlands between 1990 and 2014. The number of deaths of 3666 was highest in 1999 and decreased to 3014, i.e. by 18%, in 2014 (see Fig. 5). Corrected for age and for the demographic composition of the European population, a more significant decrease of 41% was observed (from 39.17 per 100,000 women per year in 1991 to 23.01 per 100,000 in 2014). The total number of life-years lost due to breast cancer between 1990 and 2014 in the Netherlands was estimated at 1.35 million. Despite the rising incidence in breast cancer, the total number of life-years lost per year decreased by 15.6% during this same period (Additional file 1: Table S6).

The DALY burden peaked in 2010 when breast cancer was accountable for a total of 68,500 DALYs in the Netherlands (Fig. 6). From this total, 50,000 where attributable to life years lost from early mortality (YLL) and 18,500 from disability (YLD). Since 1990, the YLL gradually decreased from 45,900 to 38,600, while the YLD increased from 13,000 to 26,000 which outweighs the reduction in YLL. Excluding DCIS from the analysis resulted in a decrease in the YLD leading to a total burden of 61,600 DALYs in 2014 versus 65,000 with inclusion of DCIS. In terms of the age distribution, patients aged 45–65 are accountable for the highest number of DALYs, which is directly correlated with the incidence and mortality of the disease.

Healthcare costs and productivity losses
The total healthcare costs of breast cancer in the Netherlands increased from €199 million in 2003 up to €692 million in 2011 (Table 2). Costs in most categories increased in absolute terms, although regarding the proportional expenditure per year, we see that only the costs related to hospital and medical professional care increased. The costs due to hospital and medical professional care accounted for €96.5 million (49% of the total budget) in 2003 and were €542.6 million (78% of the total budget) in 2011. Proportionate drug expenditure was stable between 2003 and 2007 (13%), but dropped to 7% between 2007 and 2011. The healthcare expenditure per age group (Fig. 7) is highly correlated to the incidence per age groups (Fig. 3). Total cost of productivity losses due to morbidity and mortality cumulated to €260 million and €243 million annually, respectively (Table 3). Combining the productivity losses with the total estimated healthcare expenditure, the total economic due to burden of breast cancer cumulates to €1.27 billion for 2014.

Sensitivity/scenario analyses
 Additional file 1 summarizes the results of the sensitivity analysis for the calculation of productivity losses due to morbidity and early mortality. It shows that the estimated productivity losses due to morbidity were between €258 and €334.6 million annually. Productivity losses due to mortality ranged between €221 million and €323 million annually. A scenario analysis that took future emancipation into account by matching the female gross labor participation to that of men, resulted in a total productivity of €335 million due to morbidity and €317 due to early mortality. Applying the friction cost rather than the human capital approach resulted in a productivity loss of €43 million due to morbidity and €6 million due to early mortality.

Discussion
This is the first study in The Netherlands to examine the burden of breast cancer in terms of incidence, prevalence, survival, deaths, life years

| Table 2 Healthcare costs of breast cancer in the Netherlands in Million Euro’s |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Public healthcare and prevention                  | 41.8 (21%) | 44 (18%) | 47.7 (11%) | 63.1 (9%) | 9%              |
| 1st line care                                     | 4.6 (2%)  | 5.1 (2%)  | 7.1 (2%)  | 7.5 (1%)  | 1%              |
| Hospital & medical professional care              | 96.5 (49%) | 129.8 (54%) | 280.7 (65%) | 542.6 (78%) | 78%             |
| Elderly Care                                      | 19.3 (10%) | 18.5 (8%)  | 19.1 (4%)  | 17.8 (3%)  | 3%              |
| Drugs                                            | 26.7 (13%) | 32.6 (13%) | 57.1 (13%) | 45.7 (7%)  | 7%              |
| Other healthcare providers                        | 3.1 (2%)  | 3.3 (1%)  | 5.7 (1%)  | 2.7 (0%)  | 0%              |
| Management                                       | 6.7 (3%)  | 8.9 (4%)  | 12.2 (3%) | 12.5 (2%) | 2%              |
| Total Costs in Million (€)                        | 199 (0.31%) | 243 (0.36%) | 430 (0.58%) | 696 (0.78%) | 768 (0.80%) |

*Percentage of healthcare budget
lost, DALYs, healthcare and productivity losses stratified by breast cancer stage and age using data from a national registry. This study shows an overall increase in incidence of breast cancer between 1990 and 2014 which was mainly attributable to an increase in the incidence of early breast cancer. While the incidence increased the mortality rates decreased for both early, locally advanced and metastatic breast cancer during the same time period. Despite the promising trends in survival breast cancer remains the leading cause of cancer related deaths amongst women. The rising incidence corresponds with an increase in the total economic burden of breast cancer, for which the majority of the costs concern healthcare costs followed costs for productivity losses due to morbidity and early mortality.

Although DCIS (stage 0) may not be considered as breast cancer in every country, it still needs therapeutic intervention (and in some countries hormonal treatment), has an impact on the quality of life of the patients and is associated with (treatment) costs. Therefore DCIS was included in the analysis. During the study period the incidence of early stage breast cancer increased while the incidence of locally advanced and metastatic breast cancer remained stable. The biggest rise in incidence was seen within DCIS followed by stage I diagnosis. This discrepancy could partly be explained by the introduction and continuous improvement of the national mammographic screening program, resulting in an increasing number of women diagnosed with early stage breast cancer [21, 22]. These early breast cancer cases might, however, remain asymptomatic throughout a woman’s life. If such a patient undergoes unnecessary treatment, with its associated morbidity, this is considered as overdiagnosis [21, 22]. In the literature, estimates on breast cancer cases from overdiagnosis range between 0% and 36% of the total diagnosed cases [21, 22]. In contrary to the rising incidence the breast cancer related mortality decreased between 1990 and 2014. Although the available 10-year survival data was limited to 2009, this data is still relevant as it shows ongoing trends regarding decreasing mortality. This decrease can be explained by the improved diagnostics, better treatment options including radiotherapy and targeted therapies, and the introduction of more effective drugs during this period [23, 24]. The increase in economic burden was mainly caused by a rise in costs related to hospital and medical professional care. Proportionate drug expenditure was small and stable at 13% between 2003 and 2007, and dropped further down to 7% of the total expenditure towards breast cancer between 2007 and

| Table 3 The total economic burden caused by breast cancer in the Netherlands (Human Capital Approach) |
|---------------------------------|------------|
| Healthcare Expenditure towards breast cancer in 2014 | €768 million |
| Productivity Losses due to morbidity                  | €260 million |
| Productivity Losses due to mortality                   | €243 million |
| Total economic burden                                   | €1271 million |

Fig. 7 Proportionate healthcare expenditure towards breast cancer by age groups in the Netherlands
2011. Although data on healthcare expenditure and costs for breast cancer were limited to 2011, this data is still relevant as it shows trends over time regarding increasing healthcare costs that are still ongoing and relevant for nowadays situation. Since the healthcare costs have increased in general over the last 6 years, our cost estimates might be conservative. The increase seen in indirect non-medical costs was attributable to and corresponding with the increase in incidence. The productivity losses due to morbidity where main driver of the increasing burden over time, even when DCIS was excluded from the analysis.

Comparison to other studies
Similar to our findings, other studies also showed that incidence of breast cancer is increasing. Between 1990 and 2013, age standardized incidence rates of invasive breast cancer increased by 17% globally (44 to 52 per 100,000) [8]. However, a large difference between developing countries (a 48% increase from 28 to 40 per 100,000) and developed countries (a 8% increase from 70 to 75 per 100,000) was observed [8, 25]. Our results show an increase of 34% (from 99 to 133 cases per 100,000) during the same period. Prior studies on recent trends in Belgium, Norway and Spain showed a similar increase in incidence from the 1990s and onwards [26–28]. Belgium has the highest incidence in Europe with 147.5 per 100,000 women in 2012, compared with 131.3 per 100,000 in the Netherlands. Together with Germany (122.0), the UK (129.2), Denmark (142.8) and Finland (121.0) these countries are leading in Europe [3]. Southern European countries, such as France, Spain, Portugal and Italy along with Norway and Sweden fell in the incidence range between 78.2 and 119.6 per 100,000 women and the lowest incidence was seen in eastern Europe where incidence rates were below 78.1 per 100,000 [3].

Next to the extensive screening program, the more significant increase in the incidence in the Netherlands compared to other developed countries might be explained by risk factors such as low number of offspring in the Netherlands as compared to other countries [29–33].

Breast cancer survival rates vary greatly between European countries, which could be attributable to the differences in stage of diagnosis in various countries. The Netherlands is leading in terms of survival when comparing out data to other countries in Europe [34]. For example, the one-year survival for stage IV disease between 2003 and 2009 was 69%, while it ranged between 53% and 67% in other European countries. Unfortunately, we were not able to show the difference between specific tumors types such as hormone receptor positive (HR+) or human epidermal growth factor 2 positive (HER2+) tumors as these specific data were not available. Nevertheless, it is known that the overall survival of women diagnosed with HR+/HER2+ is better when compared to triple negative breast cancers, since HR+/HER2+ tumors may respond to targeted therapies. Further research could investigate the impact of these specific tumor types on the burden of breast cancer such as incidence and survival. Although this would not change the overall burden of the disease, it will give us more understanding in inequality in burden between different types of breast cancer, also providing insights for further research and recourse allocation.

Limitations
Although we were able to stratify most of the results by age and cancer stage, this was unfortunately not possible for the economic burden due to the unavailability of these data. Data were only available on total healthcare expenditures and could not stratified on expenditures by stage of diagnosis. Apart from availability of data, the changing health related burden over time is difficult to assess, as the TNM classification changed over time. The switch from the 5th to the 6th TNM classification, for example, resulted in a shift from stage Ila to stage I as well as a shift from stage IIb to stages III, which complicates the comparison of the burden over time. To overcome these, we grouped the stages by early, locally advanced and metastatic breast cancer, but also presented all data for the individual stages. Another limitation was related to the estimation of the proportion of health-care expenditure. Since 2009 oncology drugs are financed from the hospital budget instead of the general drug budget limiting the transparency of the actual drug costs due to breast cancer.

Conclusion
This study provides a comprehensive assessment of the burden of breast cancer and subsequent trends over time in the Netherlands. Despite the promising trend of increase in survival after breast cancer diagnosis, this study shows that the BoD due to breast cancer remains significant. Furthermore, our study shows large differences in the incidence and mortality due to early, locally advanced, and metastatic breast cancer in the Netherlands.
Appendix

 Abbreviations
 BoD: Burden of Disease; CPI: Customer Price Index; DALYs: Disability Adjusted Life Years; DCIS: Ductal Carcinoma In Situ; ESR: European age Standardized Rates; HER2 + : Human Epidermal Growth factor 2 Positive; HR + : Hormone Receptor Positive; IARC: International Agency for Research on Cancer; ICD-O: International Classification of Diseases for Oncology; IKNL: Netherlands Comprehensive Cancer Organization; NCR: National Cancer Registry; RIVM: National Institute for Public Health; TNM: Tumour Node Metastasis; YLD: Years Lived with Disability; YLL: Years of Life Lost due to premature mortality

 Acknowledgements
 The authors thank the registration team of the Netherlands Comprehensive Cancer Organization (IKNL) for the collection of data for the Netherlands Cancer Registry as well as IKNL staff for scientific advice.

 Funding
 Data extraction and data analysis was funded by Pfizer (Reference number 8501115515). Pfizer did not influence the study design, the data collection, the data analysis, the interpretation of data and the writing of the manuscript.

 Availability of data and materials
 The datasets generated and/or analysed during the current study are available (upon request) in the IKNL repository, http://cijfersoverkanker.nl

 Authors’ contributions
 MHR, EPD and GTV developed the design of this study, GTV and EPD carried out the data collection and conducted the analyses. MJP, GLM and IRK contributed to the interpretation of the data. All authors contributed in the conceptualization of the paper. GTV and MHR Drafted the manuscript. All authors revised it critically for intellectual content. All authors read and approved the final manuscript.

 Ethics approval and consent to participate
 No ethical approval was required as an existing database was used and aggregated data was provided by IKNL.

 Consent for publication
 Not applicable.

 Competing interests
 Mark Rozenbaum is employed by Pfizer. All other authors declare that they have no competing interests.

 Publisher’s Note
 Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

 Author details
 1Department of Pharmaco-Epidemiology and Economics, University of Groningen, PO Box 72, Groningen 9700 AB, The Netherlands. 2Department of Public Affairs, Pfizer, Rotterdam, The Netherlands. 3Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. 4Department of Clinical Pharmacy, Deventer Hospital, Deventer, The Netherlands. 5Groningen Research Institute of Pharmacy, PharmacoTherapy, - Epidemiology & -Economics University of Groningen, Groningen, The Netherlands. 6Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.

 Received: 27 July 2017 Accepted: 21 February 2018
 Published online: 07 March 2018

 References


